Syed Ali, MD
Interventional Cardiology · Oklahoma City, OKNPI 1760612014
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $13,669 of the $19,207 with a category attached, or 71.2%. 18 manufacturers reported payments, led by Edwards Lifesciences at 42.8% of the total. 2025 is the largest year on record at $7,624, more than ten times the $110 reported in 2019.
Across 168 payments — averaging $114.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$8K
- Abbott$4K
- Boston Scientific$3K
- Medtronic$3K
- Penumbra, Inc.$1K
- Abiomed$389
- plus $369 from 12 others
What the payments were for
- Travel & lodging$13,66971%
- Food & beverage$5,53729%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 79 | $8,218 |
| Abbott | 33 | $3,557 |
| Boston Scientific | 12 | $2,841 |
| Medtronic(2 entities) | 21 | $2,604 |
| Penumbra, Inc. | 4 | $1,229 |
| Abiomed | 5 | $389 |
| Biotronik Inc. | 1 | $117 |
| Astellas Pharma US Inc | 3 | $50 |
| Pacira Pharmaceuticals Incorporated | 1 | $36 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Amgen | 1 | $24 |
| Terumo Medical Corporation | 1 | $20 |
| Merck | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Teleflex LLC | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,063
- RESOLUTE ONYX$1,562
- RUBY Coil$1,229
- TRICLIP$1,220
- WATCHMAN Access System$1,204
- SAPIEN 3 Ultra RESILIA$1,000
- MitraClip System$937
- MitraClip$809
- PASCAL$729
- Impella$293
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$242
- COREVALVE EVOLUT R$129
- Orsiro Mission$117
How this compares
$19,207 in reported general payments places this provider in the 75th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 171 | $156,432 |
| EntrestoSacubitril/Valsartan | 78 | $72,090 |
| XareltoRivaroxaban | 30 | $19,331 |
| VascepaIcosapent Ethyl | 27 | $12,005 |
| BrilintaTicagrelor | 12 | $11,726 |
| FarxigaDapagliflozin Propanediol | 11 | $8,703 |
| Atorvastatin Calcium | 591 | $7,313 |
| Repatha PushtronexEvolocumab | 11 | $7,174 |
| Torsemide | 150 | $6,546 |
| Prasugrel Hcl | 67 | $6,108 |
| Telmisartan | 123 | $5,871 |
| Potassium Chloride | 326 | $5,075 |
| Ranolazine ErRanolazine | 41 | $3,195 |
| Amlodipine Besylate | 369 | $2,966 |
| Metoprolol Succinate | 200 | $2,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $16 | $156,432171 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Oklahoma City
- George ChrysantOklahoma City$524K
- Jeffrey SparlingOklahoma City$231K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Marcus SmithOklahoma City$67K
- Parker TruongOklahoma City$44K
- Mohammad GhaniOklahoma City$38K
- Timothy DalyOklahoma City$31K
- Branislav SchifferdeckerOklahoma City$26K
- Mohit PahujaOklahoma City$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.